Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...

UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development. New Jersey-based UroGen forked ...

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for ...

High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases. Nautilus, a phase 1b/2 trial of combining oral ...

In Zhejiang University's zebrafish study, lacking the CTLA-4 gene led to weight loss, intestinal inflammation, and disrupted gut bacteria, similar to human inflammatory bowel disease (IBD) Detailed ...

SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, ...

Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal ...

Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.